Construction of CXCR4 Receptor-Targeted CuFeSe2 Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy
International Journal of Nanomedicine · 2024
DOI: 10.2147/ijn.s470367 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2024. Verfasst von Wenlu Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Receptors, CXCR4, Theranostic Nanomedicine, Photothermal Therapy, Magnetic Resonance Imaging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
Targeting, imaging, and treating tumors represent major clinical challenges. Developing effective theranostic agents to address these issues is an urgent need.
Methods
We introduce an "all-in-one" tumor-targeted theranostic platform using CuFeSe2-based composite nanoparticles (CuFeSe2@PA) for magnetic resonance (MR) and computed tomography (CT) dual model imaging-guided hyperthermia tumor ablation. Plerixafor (AMD3100) is bonded to the surface of CuFeSe2 as a targeting unit. Due to the robust interaction between AMD3100 and the overexpressed Chemokine CXC type receptor 4 (CXCR4) on the membrane of 4T1 cancer cells, CuFeSe2@PA specifically recognizes 4T1 cancer cells, enriching the tumor region.
Results
CuFeSe2@PA serves as a contrast agent for T2-weighted MR imaging (relaxivity value of 1.61 mM-1 s-1) and CT imaging. Moreover, it effectively suppresses tumor growth through photothermal therapy (PTT) owing to its high photothermal conversion capability and stability, with minimized side effects demonstrated both in vitro and in vivo.
Discussion
CuFeSe2@PA nanoparticles show potential as dual-mode imaging contrast agents for MR and CT and provide an effective means of tumor treatment through photothermal therapy. The surface modification with Plerixafor enhances the targeting ability of the nanoparticles, performing more significant efficacy and biocompatibility in the 4T1 cancer cell model. The study demonstrates that CuFeSe2@PA is a promising multifunctional theranostic platform with clinical application potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
ORCID-Profile: Jing Zhang, Jiong Liu, Shaozhi Fu
Zitieren
APA
Li, W., Gong, Y., Zhang, J., Liu, J., Li, J., Fu, S., Ren, W. X., & Shu, J. (2024). Construction of CXCR4 Receptor-Targeted CuFeSe2 Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s470367
Vancouver
Li W, Gong Y, Zhang J, Liu J, Li J, Fu S, et al. Construction of CXCR4 Receptor-Targeted CuFeSe2 Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy. International Journal of Nanomedicine. 2024. doi:10.2147/ijn.s470367
BibTeX
@article{Li2024,
author = {Li, Wenlu and Gong, Yaolin and Zhang, Jing and Liu, Jiong and Li, Jiali and Fu, Shaozhi and Ren, Wen Xiu and Shu, Jian},
title = {Construction of CXCR4 Receptor-Targeted CuFeSe2 Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy},
journal = {International Journal of Nanomedicine},
year = {2024},
doi = {10.2147/ijn.s470367}
}
EUVIMED